We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Cancer stem cells (CSCs), also referred to as cancer initiating cells, represent a minority population of cells within a tumor. CSCs can self-renew and give rise to terminally differentiated cells. Many cancer disease models propose that the existence of CSCs contribute to cancer metastasis. While conventional cancer treatments often eliminate terminally differentiated cells within a tumor, CSCs have an inherent ability to be more resistant to such treatments. Therefore, the ability to properly isolate and culture these rare cells is a first step towards finding the right treatment. CSCs, when cultured in suspension, aggregate to form spheres known as tumorspheres.
This protocol outlines the steps needed to enrich for cancer stem cells under serum-free conditions using PRIME-XV Tumorsphere Serum-Free Medium. For more information on this medium, please refer to the product insert.
Efficient tumorsphere formation of MCF-7 cells under PRIME-XV Tumorsphere SFM (left) compared to control 10% serum-containing DMEM (right). Images taken at 10X magnification.
The following cancer stem cell protocols are optimized for tumorsphere formation using HeLa, MCF-7 and A549 cells. Procedures for optimal growth conditions should be determined for each application and cell type as appropriate. Safe laboratory procedures should be followed and protective clothing should be worn when handing this medium. The acute and chronic effects of over-exposure to this medium are unknown.
* TrypLE is a registered trademark of Life Technologies.